<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02009579</url>
  </required_header>
  <id_info>
    <org_study_id>BGOG-cx1/ENGOT-cx1</org_study_id>
    <nct_id>NCT02009579</nct_id>
  </id_info>
  <brief_title>ENGOT-cx1/BGOG-cx1: 3 Weekly Carboplatin/Paclitaxel With or Without Nintedanib in Cervix Cancer</brief_title>
  <official_title>BGOG-cx1/ENGOT-cx1: &quot;Randomized Double-blind Phase II Study Comparing 3-weekly Carboplatin + Paclitaxel With or Without Concomitant and Maintenance Nintedanib (NINTEDANIB) in Advanced or Recurrent Cervical Carcinoma.&quot;</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Belgian Gynaecological Oncology Group</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Grupo Español de Investigación en Cáncer de Ovario</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Mario Negri Gynecologic Oncology group (MANGO)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Multicenter Italian Trials in Ovarian Cancer (MITO)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>North Eastern Germany Society of Gynaecologic Oncology</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Belgian Gynaecological Oncology Group</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Indication:

      Treatment of subjects with advanced (FIGO stage IVB) or recurrent cervical cancer, prior
      radiochemotherapy or neo-adjuvant chemotherapy is allowed.

      Study design:

      This is a phase II randomized, double blind and placebo controlled trial evaluating the
      efficacy of Nintedanib/placebo in combination with the standard carboplatin and paclitaxel
      followed by Nintedanib/placebo maintenance in the treatment of patients with advanced or
      recurrent cervical cancer.

      A total of 120 patients will be randomized between the experimental and control arm in a 1:1
      ratio. Randomization will be stratified for 1previous chemotherapy for metastatic disease
      (yes/no) and 2disease status (Stage IVB primary versus recurrent disease).

      Experimental arm: Subjects will receive 6 cycles of 3-weekly carboplatin (AUC 5) + paclitaxel
      (175 mg/m2) and Nintedanib 200 mg BID followed by Nintedanib maintenance until progression or
      for a total maximum duration of 120 weeks.

      Control arm: Subjects will receive 6 cycles of 3-weekly carboplatin (AUC 5) + paclitaxel (175
      mg/m2) and placebo 200 mg BID followed by placebo maintenance until progression or for a
      total maximum duration of 120 weeks.

      Subjects without evidence of disease progression after completion or discontinuation of the
      study treatment will be followed until radiographic disease progression, withdrawal of
      consent or death.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>March 2014</start_date>
  <completion_date type="Anticipated">July 2020</completion_date>
  <primary_completion_date type="Anticipated">December 2017</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Progression free survival</measure>
    <time_frame>1.5 years after LPI</time_frame>
    <description>Primary objective:
The purpose of this trial is to determine if chemotherapy (carboplatin/paclitaxel) plus Nintedanib (BIBF 1120) can improve progression free survival compared to chemotherapy (carboplatin/paclitaxel) plus placebo in patients with advanced or recurrent cervical cancer.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Safety and toxicity</measure>
    <time_frame>5 years after LPI</time_frame>
    <description>Secondary objectives:
To evaluate the safety and toxicity reported for of the combination regimen</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>5 years after LPI</time_frame>
    <description>To evaluate the response rate according to RECIST 1.1</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient health status</measure>
    <time_frame>5 years after LPI</time_frame>
    <description>To explore the effect of Nintedanib on patient reported health status as measured by EORTC-QOL-Cx 24 and EORTCQLQ-C30 questionnaires</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>5 years after LPI</time_frame>
    <description>To evaluate the overall survival</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">120</enrollment>
  <condition>Uterine Cervical Neoplasms</condition>
  <arm_group>
    <arm_group_label>Experimental arm</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Nintedanib/vargatef</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Comparator arm</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nintedanib</intervention_name>
    <description>Subjects will receive 6 cycles of 3-weekly carboplatin (AUC 5) + paclitaxel (175 mg/m2) and Nintedanib 200 mg BID followed by Nintedanib maintenance until progression or for a total maximum duration of 120 weeks.</description>
    <arm_group_label>Experimental arm</arm_group_label>
    <other_name>Vargatef</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Subjects will receive 6 cycles of 3-weekly carboplatin (AUC 5) + paclitaxel (175 mg/m2) and placebo 200 mg BID followed by placebo maintenance until progression or for a total maximum duration of 120 weeks.</description>
    <arm_group_label>Comparator arm</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Female subjects more than 18 years of age

          -  Histologically or cytologically confirmed advanced ([FIGO] stage IVB), or
             recurrent/persistent squamous cell carcinoma, adenosquamous carcinoma, or
             adenocarcinoma of the cervix will be eligible.

          -  Prior treatment with angiogenesis inhibitors is allowed

          -  Up to one prior line of chemotherapy for metastatic cervical cancer is allowed.

               -  Treatment of primary disease with concomitant cisplatinum chemotherapy during
                  radiotherapy is allowed and does not count as a line of chemotherapy for
                  metastatic disease.

               -  Treatment of primary disease with neoadjuvant chemotherapy before radical local
                  surgery is allowed and does not count as a line of chemotherapy for metastatic
                  disease.

               -  Treatment of primary disease with neoadjuvant chemotherapy before radical local
                  surgery followed by adjuvant radiochemotherapy is allowed and does not count as a
                  line of chemotherapy for metastatic disease.

               -  Treatment of primary disease with neoadjuvant chemotherapy before radical local
                  surgery followed by adjuvant radiotherapy is allowed and does not count as a line
                  of chemotherapy for metastatic disease.

          -  Life expectancy at least 3 months.

          -  ECOG Performance status score of 0 or 1

          -  At least one measurable lesion according to RECIST 1.1 criteria

          -  Signed and dated written informed consent prior to admission to the study in
             accordance with ICH-GCP guidelines and to the local legislation

        Exclusion Criteria:

          -  Known hypersensitivity to the trial drugs or to their excipients (including peanut or
             soya).

          -  Brain or leptomeningeal metastases.

          -  Centrally located tumors with radiographic evidence (CT or MRI) of local invasion of
             major blood vessels.

          -  Tumor infiltrating the mucosa of the bowel or bladder, or known fistulas between the
             tumor and the gastrointestinal or urinary tract.

          -  Radiographic evidence of cavitary or necrotic tumours

          -  Treatment with other investigational drugs or treatment in another clinical trial
             within the past 4 weeks before start of therapy or concomitantly with the trial.

          -  Therapeutic anticoagulation with drugs requiring INR monitoring (except low-dose
             heparin and/or heparin flush as needed for maintenance of an in-dwelling intravenous
             devise) or anti-platelet therapy (except for low-dose therapy with acetylsalicylic
             acid &lt;325 mg per day).

          -  Major injuries within the past 4 weeks prior to start of study treatment with
             incomplete wound healing and/or planned surgery during the on-treatment study period.

          -  History of clinically significant haemorrhagic or thromboembolic event in the past 6
             months.

          -  Known inherited predisposition to bleeding or thrombosis.

          -  Significant cardiovascular diseases ( i.e. uncontrolled hypertension, unstable angina
             within the past 6 months, history of infarction within the past 12 months prior to
             start of study treatment, congestive heart failure &gt; NYHA II, serious cardiac
             arrhythmia, pericardial effusion).

          -  History of a cerebral vascular accident, transient ischemic attack or subarachnoid
             haemorrhage within the past 6 months.

          -  Abnormal renal, liver or bone marrow function defined as:

               -  Proteinuria CTCAE grade 2 or greater

               -  Creatinin &gt; 2 ULN or GFR &lt; 30 ml/min

               -  Hepatic function: total bilirubin outside of normal limits; ALT or AST &gt; 1.5 ULN
                  in pts without liver metastasis. For Pts with liver metastases: total bilirubin
                  outside of normal limits, ALT or AST &gt; 2.5 ULN

               -  Coagulation parameters: International normalised ratio (INR) &gt; 2, prothrombin
                  time (PT) and partial thromboplastin time (PTT) &gt; 50% of deviation of
                  institutional ULN

               -  Absolute neutrophil count ( ANC) &lt; 1500/µl, platelets &lt; 100000/µl, haemoglobin &lt;
                  9.0 g/dl

          -  Other malignancies within the past 3 years or other malignancy with recurrence in the
             past 3 years or with high risk of recurrence in the first year. In exception to this
             rule, the following malignancies may be included: non-melanomatous skin cancer (if
             adequately treated) , any premalignant (e.g. in situ) carcinoma, or basocellular
             carcinoma.

          -  Active serious infections in particular if requiring systemic antibiotic or
             antimicrobial therapy.

          -  Active or chronic hepatitis C and/or B infection or known HIV infection (based on
             medical file, only for Italy a mandatory screening test for HIV should be performed
             for all patients who did not have this test within the last 3 months before the study
             treatment start).

          -  Gastrointestinal disorders or abnormalities that would interfere with absorption of
             the study drug.

          -  Serious illness or concomitant non-oncological disease such as neurologic,
             psychiatric, infectious disease or active ulcers (gastro-intestinal tract, skin) or
             laboratory abnormality that may increase the risk associated with study participation
             or study drug administration and in the judgment of the investigator would make the
             patient inappropriate for entry into the study.

          -  Patients of child-bearing potential who are sexually active and unwilling to use a
             medically acceptable method of contraception (e.g. such as implants, injectables,
             combined oral contraceptives, some intrauterine devices or vasectomized partner or
             sexual abstinence for participating females) during the trial and for at least three
             months after end of active therapy.

          -  Pregnancy or breast feeding, female patients must have a negative pregnancy test
             (β-HCG test in urine or serum) prior to commencing study treatment, if applicable.

          -  Psychological, familial, sociological or geographical factors potentially hampering
             compliance with the study protocol and follow-up schedule.

          -  Active alcohol or drug abuse.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Ignace Vergote, MD</last_name>
    <phone>+32(0)16 344207</phone>
    <email>bgog@engot.eu</email>
  </overall_contact>
  <location>
    <facility>
      <name>CHU Saint-Pierre</name>
      <address>
        <city>Bruxelles</city>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Institut Jules Bordet</name>
      <address>
        <city>Bruxelles</city>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Grand Hopital de Charleroi</name>
      <address>
        <city>Charleroi</city>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>UZ Antwerpen</name>
      <address>
        <city>Edegem</city>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>AZ Groeninge</name>
      <address>
        <city>Kortrijk</city>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>UZ Leuven</name>
      <address>
        <city>Leuven</city>
        <zip>3000</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Ignace Vergote, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHR Citadelle</name>
      <address>
        <city>Liege</city>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>CHU de Liège</name>
      <address>
        <city>Liège</city>
        <zip>4000</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christine Gennigens, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Clinique et maternite St. Elisabeth</name>
      <address>
        <city>Namur</city>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Cliniques Universitaires mont godinne</name>
      <address>
        <city>Yvoir</city>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Charité Med Uni Berlin</name>
      <address>
        <city>Berlin</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Radoslav Chekerov, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Carl Gustav Carus Dresden</name>
      <address>
        <city>Dresden</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Pauline Wimberger, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Kliniken Essen Mitte</name>
      <address>
        <city>Essen</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Georg-August University Göttingen</name>
      <address>
        <city>Gottingen</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Medical University Greifswald</name>
      <address>
        <city>Greifswald</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alexander Mustea, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>University Tübingen</name>
      <address>
        <city>Tubingen</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Andreas Hartkopf, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centro Riferimento Oncologico</name>
      <address>
        <city>Aviano</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Roberto Sorio, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Spedali Civili</name>
      <address>
        <city>Brescia</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Germana Tognon, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliera Cannizzaro</name>
      <address>
        <city>Catania</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Paolo Scollo, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>National Cancer Institute</name>
      <address>
        <city>Milano</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ketta Lorusso, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Istituto Nazionale Tumori-Pascale Naples</name>
      <address>
        <city>Naples</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Padova Istituti Oncologico Veneto</name>
      <address>
        <city>Padova</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Maria Nicoletto, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>University Pisa</name>
      <address>
        <city>Pisa</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Angiolo Gadducci, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>AUSL Reggio Emilia</name>
      <address>
        <city>Reggio Emilia</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>allesandra bologna, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Poloclinico A Gemelli</name>
      <address>
        <city>Rome</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Giovanni Scambia, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Mauriziano -Torino</name>
      <address>
        <city>Torino</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>S. Anna Torino</name>
      <address>
        <city>Torino</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Paolo Zola, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Provincial Reina Sofia</name>
      <address>
        <city>Córdoba</city>
        <zip>14004</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Maria Jesús Rubio, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>H. Ramón y Cajal</name>
      <address>
        <city>Madrid</city>
        <zip>28034</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Eva Maria Guerra, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Clinico San Carlos</name>
      <address>
        <city>Madrid</city>
        <zip>28040</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Antonio Casado, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Morales Meseguer</name>
      <address>
        <city>Murcia</city>
        <zip>30008</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Helena Garcia, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Son Llatzer</name>
      <address>
        <city>Palma Mallorca</city>
        <zip>07198</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Isabel Bover, MD</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>Germany</country>
    <country>Italy</country>
    <country>Spain</country>
  </location_countries>
  <link>
    <url>http://www.bgog.eu/</url>
    <description>BGOG website</description>
  </link>
  <link>
    <url>http://www.esgo.org/engot/Pages/AboutENGOT.aspx</url>
    <description>ENGOT website</description>
  </link>
  <verification_date>July 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 24, 2013</study_first_submitted>
  <study_first_submitted_qc>December 9, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 12, 2013</study_first_posted>
  <last_update_submitted>July 28, 2017</last_update_submitted>
  <last_update_submitted_qc>July 28, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">August 1, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Uterine Cervical Cancer</keyword>
  <keyword>Paclitaxel</keyword>
  <keyword>Carboplatin</keyword>
  <keyword>Nintedanib</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Uterine Cervical Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Paclitaxel</mesh_term>
    <mesh_term>Nintedanib</mesh_term>
    <mesh_term>Albumin-Bound Paclitaxel</mesh_term>
    <mesh_term>Carboplatin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

